We are live on ! Find out more
AIP

Arrowpoint Investment Partners Portfolio holdings

AUM $459M
1-Year Est. Return 93.97%
This Fund
S&P 500
This Quarter Est. Return
+33.31%
1 Year Est. Return
+93.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$459M
AUM Growth
+$347M
Cap. Flow
+$245M
Cap. Flow %
53.32%
Top 10 Hldgs %
63.7%
Holding
167
New
86
Increased
23
Reduced
20
Closed
38

Top Buys

Rank Stock Value
1
C icon
Citigroup
C
+$30.6M
2
GS icon
Goldman Sachs
GS
+$30.2M
3
XOM icon
ExxonMobil
XOM
+$26.8M
4
GPN icon
Global Payments
GPN
+$26.4M
5
NVDA icon
NVIDIA
NVDA
+$25.8M

Top Sells

Rank Stock Value
1
ASX icon
ASE Group
ASX
+$3.89M
2
ASND icon
Ascendis Pharma A/S
ASND
+$2.71M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$2.01M
4
PFE icon
Pfizer
PFE
+$2M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.93M

Sector Composition

Rank Sector Weight
1 Miscellaneous 28.72%
2 Healthcare 18.58%
3 Financials 14.08%
4 Industrials 12.67%
5 Technology 12.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRVL icon
76
Marvell Technology
MRVL
$201B
$439K 0.1%
+1,474
New +$296K
ALMS
77
Alumis Inc
ALMS
$1.44B
$433K 0.09%
15,396
+3,365
+28% +$78.3K
ILMN icon
78
Illumina
ILMN
$33B
$416K 0.09%
2,368
-658
-22% -$96.3K
PTGX icon
79
Protagonist Therapeutics
PTGX
$9.43B
$404K 0.09%
3,298
-6,036
-65% -$630K
AVR
80
Anteris Technologies
AVR
$881M
$386K 0.08%
+39,233
New +$298K
COGT icon
81
Cogent Biosciences
COGT
$6.03B
$375K 0.08%
9,698
-4,086
-30% -$143K
HPE icon
82
Hewlett Packard
HPE
$69B
$370K 0.08%
+8,193
New +$296K
CERT icon
83
Certara
CERT
$1.21B
$356K 0.08%
+54,326
New +$306K
IMVT icon
84
Immunovant
IMVT
$8.11B
$348K 0.08%
+9,043
New +$276K
MCHP icon
85
Microchip Technology
MCHP
$40.3B
$345K 0.08%
+3,782
New +$337K
RARE icon
86
Ultragenyx Pharmaceutical
RARE
$1.51B
$328K 0.07%
+9,829
New +$244K
BLFS icon
87
BioLife Solutions
BLFS
$1.72B
$328K 0.07%
+11,612
New +$271K
ADPT icon
88
Adaptive Biotechnologies
ADPT
$3.87B
$325K 0.07%
+15,149
New +$232K
MRVI icon
89
Maravai LifeSciences
MRVI
$1.09B
$316K 0.07%
+50,615
New +$219K
CYRX icon
90
CryoPort
CYRX
$801M
$315K 0.07%
+20,067
New +$257K
BLTE
91
Belite Bio
BLTE
$7.8B
$309K 0.07%
2,008
-3,996
-67% -$612K
TSM icon
92
TSMC
TSM
$2.22T
$306K 0.07%
+640
New +$260K
TXG icon
93
10x Genomics
TXG
$8.16B
$296K 0.06%
+7,725
New +$202K
SNDX icon
94
Syndax Pharmaceuticals
SNDX
$1.84B
$279K 0.06%
+12,755
New +$265K
YUMC icon
95
Yum China
YUMC
$14.8B
$265K 0.06%
+6,473
New +$296K
MLTX icon
96
MoonLake Immunotherapeutics
MLTX
$1.28B
$263K 0.06%
+13,489
New +$245K
BIOA
97
BioAge Labs
BIOA
$440M
$257K 0.06%
10,472
-10,324
-50% -$187K
ACI icon
98
Albertsons Companies
ACI
$6.09B
$253K 0.06%
+18,689
New +$299K
GPCR icon
99
Structure Therapeutics
GPCR
$3.38B
$249K 0.05%
4,645
+455
+11% +$20.1K
TNGX icon
100
Tango Therapeutics
TNGX
$3.8B
$239K 0.05%
7,658
-12,805
-63% -$317K
2 3
4
5 6

Similar funds

VIM
VELA Investment Management New Albany, Ohio $459M AUM 18.61% 1-Year Est. Return
AM
Atwater Malick Lancaster, Pennsylvania $459M AUM 37.25% 1-Year Est. Return
SSC
Syverson Strege & Co West Des Moines, Iowa $459M AUM 27.74% 1-Year Est. Return
RFN
RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return
PWS
Peterson Wealth Services South Ogden, Utah $459M AUM 42.99% 1-Year Est. Return
GCM
G2 Capital Management Columbus, Ohio $459M AUM 18.56% 1-Year Est. Return
CIM
Coleford Investment Management Toronto, Ontario, Canada $459M AUM 23.79% 1-Year Est. Return
RAG
RIA Advisory Group Des Moines, Iowa $460M AUM 29% 1-Year Est. Return

Arrowpoint Investment Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Arrowpoint Investment Partners held 167 positions worth $459M, up 308% from $113M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Arrowpoint Investment Partners deployed $245M of net new capital in Q2 2026, opening 86 new positions and adding to 23 existing holdings. Its largest new stake was Citigroup: 235,033 shares worth $32.9M.

By sector, the portfolio is most concentrated in Miscellaneous at 29% of assets, down from 45% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $2.01M trimmed.

  • Arrowpoint Investment Partners's largest Q2 2026 buy was Citigroup: 235,033 shares worth $32.9M.
  • Arrowpoint Investment Partners added most to Insmed in Q2 2026, an estimated $2.8M increase.
  • Arrowpoint Investment Partners's biggest Q2 2026 reduction was Ionis Pharmaceuticals, cutting an estimated $2.01M.
  • Arrowpoint Investment Partners fully exited ASE Group in Q2 2026, selling an estimated $3.89M.
  • Arrowpoint Investment Partners's ten largest holdings make up 64% of its $459M portfolio in Q2 2026.
  • Arrowpoint Investment Partners opened 86 new positions and closed 38 in Q2 2026.
  • Arrowpoint Investment Partners's portfolio value rose 308% quarter-over-quarter to $459M.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.